Royalty Report: Drugs, Biotechnology, Stem cells – Collection: 47933

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Biotechnology
  • Stem cells
  • Medical
  • Therapeutic
  • Supply
  • Disease
  • Drug Discovery
  • cell therapy
  • Specialty
  • Diagnostic
  • Surgical
  • Genome
  • Cancer
  • Cell Line

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 47933

License Grant
The Spanish University patent families referred to as PCX006 and PCX007 are the subject of a co ownership agreement with the Spanish Licensee. Under the terms of this agreement, the University assigned all exploitation rights, including the right to license or sub-license to third parties.
License Property
University signed an agreement for the Assignment of the Rights to Exploit Spanish invention patents no. 200402355, entitled “IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE”, and no. 200402083, entitled “Biomaterial for suture”

PCX006 is a patent family claiming a non osteochondral derived multipotent adult stem cell population characterized by a set of biological markers.
PCX007 is a patent family claiming an adipose derived stem cell composition characterized by a panel of cell surface markers, methods of preparation of such a composition and adipose tissue derived stromal stem cells in treating fistula and wounds.

(WO2006037649/11/167,061) IDENTIFICATION AND INSOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
The present invention relates to isolated multipotent adult cells which are isolated from non-osteochondral mesenchymal tissue and are characterized by the presence and absence of a set of cell surface markers. The invention also relates to a method for identifying and isolating a population of said cells, as well as to the applications thereof, for example, in the manufacture of a pharmaceutical composition for the repair and regeneration of tissues.

Field of Use
The Licensee is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells.

IPSCIO Record ID: 273421

License Grant
The Parties reached a mutual understanding that the License Agreement drafted in 2001 no longer accurately reflected the business model of the Licensee, and that it contained certain restrictions and milestones that were not optimal for the commercialization of the Invention portfolio.

With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.

License Property
This license is for certain inventions, generally characterized as Adipose-Derived Stem Cells and Lattices.

The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.

Product means Research Product and Clinical Product.

Field of Use
The Field means any and all products and/or services for the research, diagnosis, and/or therapy of disease and/or disorders in humans and for cosmetic applications in humans.

Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.

The patented Celution® family of products process patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.  Licensee commercialization model is based on the sale of Celution® Systems and on generating recurring revenues from the single-use consumable sets.

Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytori’s core product, the Celution® System, provides physicians with clinical grade stem and regenerative cells.

IPSCIO Record ID: 47833

License Grant
Two Spanish Licensors, including a University, have an exclusive license agreement with a Spanish Licensee of all rights to the Patent.
License Property
The agreement is for a patent under number PCT/IB2009/006597 entitled Uses of Mesenchymal Stem Cells. Licensee has the intention of applying for future international extensions of such application, hereinafter, all of them jointly referred to as the Patent.
Field of Use
Systemic inflammatory response syndrome (SIRS) is an inflammatory state of the whole body without a specific source of infection. It can be caused by many factors, including but not limited to trauma, surgery, adrenal insufficiency, pulmonary embolism, myocardial infarction, hemorrhage, anaphylaxis, drug overdose, immunodeficiency and burns. There are four major diagnostic symptoms of SIRS, as listed below, but the presence of any two of these is sufficient for a diagnosis.

IPSCIO Record ID: 26667

License Grant
We acquired the Exclusive worldwide rights to US Patent # 6129911, for Liver Stem Cells from Licensor, a non-profit  hospital.  The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.
License Property
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.  (The Company has an exclusive, long-term license agreement for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs)  US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;  US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;  US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;  US Patent #4,795,459, Implantable Prosthetic Device (Endothelial), expires January 3, 2006;  US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;  US Patent #6,858,146, Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and  US Patent #6,872,389, Liver Stem Cell, expires on July 8, 2019.)

IPSCIO Record ID: 340079

License Grant
The Agreement grants the patent rights. The contract grants Licensee access to proprietary process of expanding the master cell bank of Licensor.
License Property
9,803,176 – The Patent is titled Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses.
Field of Use
The field of use means transwell/co culture is for enhancing autologous cell stem cells.

The transwell migration assay is a commonly used test to study the migratory response of endothelial cells to angiogenic inducers or inhibitors. This assay is also known as the Boyden or modified Boyden chamber assay.

IPSCIO Record ID: 263

License Grant
The Hospital hereby grants the Licensee an exclusive, royalty-bearing license under its Patent Rights in the License Field and the License Territory.
License Property
Pathfinder Cells shall mean a mixed population of mammalian cells, with a mixed CD90 positive phenotype and CD34 negative phenotype, isolated using the methodology described in the patent WO/2006/120476, and which are capable of facilitating, or initiating the repair of mammalian tissue following, by way of example only, insult with an exogenous agent, or degenerative disease, or through the biological ageing processes.

Patent rights shall mean the U.S. Patent Application Number 11/438,790, filed on May 22, 2006 or the equivalent of such application as well as issued patent applications including U.S. Patent Application Number 11/410, 412, 10/984, 645, and 11/132, 687.

Field of Use
Pathfinder Cells are a newly identified mammalian cell type  that have the ability to stimulate tissue regeneration in a number of different organs. PCs are not stem cells and are distinguishable from cell types being developed by other companies for use in regenerative medicine through cell surface and other markers.

IPSCIO Record ID: 829

License Grant
The University in Scotland hereby grants the Licensee an exclusive worldwide, non-transferable royalty bearing license to use and exploit the Licensed Technology in the Field for the purpose of developing, manufacturing, distributing and selling Products on the terms and conditions contained in the Agreement.
License Property
The University has created and developed certain technology relating to cell regeneration which has shown potential for use is developing cell based therapies for diabetes and other progressive degenerative conditions.

Pathfinder Cells means a mixed population of mammalian cells, with a mixed CD90 positive phenotype and CD34 negative phenotype, isolated using the methodology described in the Patents, and which are capable of facilitating, or initiating the repair of mammalian tissue following, by way of example only, insult with an exogenous agent, or degenerative disease, or through the biological ageing processes.

Pathfinder Cells are a newly identified mammalian cell type that have the ability to stimulate tissue regeneration in a number of different organs. PCs are not stem cells and are distinguishable from cell types being developed by other companies for use in regenerative medicine through cell surface and other markers.

Field of Use
The Field means a field of use encompassing all uses of the Licensed Technology for the application of human and animal Pathfinder Cells as therapeutics, vaccines, diagnostic, biomaterials and research tools.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 297144

License Grant
The Company acquired an exclusive license (and a right to sub-license) to the technology and know-how relating to an isolation and commercial scale expansion methodology of GMP grade human umbilical cord mesenchymal stem/stromal cells (“MSC”).
License Property
Mesenchymal stem cells (“HucMSC”) – a methodology for producing large numbers of clinical-grade pooled human umbilical cord.

Mesenchymal stem cells is for the medical research and biotech community that offers large volumes of high-quality, low passage human umbilical cord mesenchymal stem cells with minimal batch-to-batch variability.

Field of Use
This agreement pertains to the medical industry relating to stem cells.

IPSCIO Record ID: 26091

License Grant
University grants Company a sole and exclusive worldwide License, under the Technology, Existing Patent Rights (to the extent not owned by the Company) and Developed Patent Rights  to make, have made, use and sell Product and Process,  including the right to grant sublicenses.
License Property
Existing Patent Rights shall mean (i) A Method for Isolating, Purifying and Culturally Expanding Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 615,430); (ii) Monoclonal Antibodies Specific for Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 716,917); (iii) A Method and Device for Enhancing the Implantation and Differentiation of Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 614,915); and (iv) A Method and Device for Treating Connective Tissue Disorders (U.S. Patent Application No. 614,912); any division, continuation, or continuation-in-part thereof and any foreign patent application or equivalent corresponding thereto and any Letters Patent or the equivalent thereof in any country of the world.

Developed Patent Rights shall mean any and all patents and patent applications anywhere in the world which contains one or more claims directed to Technology, which is not an Existing Patent Right.

Technology shall mean any and all existing or future information, technical data, inventions, discoveries or know-how, and materials whether or not patented or patentable, related to or useful for the  identification, isolation, purification, propagation or of use of mesenchymal stem cells and/or cells or products derived from or produced by mesenchymal stem cells, which are conceived, developed or reduced to practice by an Investigator while performing research at the University.

IPSCIO Record ID: 246210

License Grant
The Licensor grants the Licensee an exclusive licence to use, process, test and store the Materials (umbilical cord tissue samples) and Mesenchymal Stem Cells;  produce Licensed Product, including the creation of Derivatives and Progeny from Materials;  supply Licensed Product to third parties and to provide services in relation to such Licensed Product to third parties; and sub-licence its rights to Affiliates and to third party service providers.
License Property
The procurement of Mesenchymal Stem Cells derived from umbilical cord blood or placenta to be used for research purposes.  Materials are only for use in humans or for human application.
Field of Use
Cord Blood/Tissue, derived cells, progeny or derivative may be supplied and used in research projects if conducted in accordance with certain conditions.

License is for the methodology for producing clinical-grade pooled human umbilical cord derived mesenchymal stem/stromal cells (“HucMSC”) at industrial scale.

IPSCIO Record ID: 28541

License Grant
University grants Licensee an Exclusive license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory. Licensee may grant sublicenses in the Licensed Field of Use only during the Exclusive term and only if Licensee is developing or selling Licensed Products, Required Sublicensing.
License Property
University has an assignment of an invention a target and associated compounds useful for regenerative medicine. It is entitled Notch-Mediated Tissue and Organ Repair through Control of Endogenous Stem and Progenitor Cell Behavior.

Licensed Patent means U.S. Patent Application, Serial Number 11/078,899.  

Stem cells have a capacity both for self-renewal and the generation of differentiated cell types. This pluripotentiality makes stem cells unique. In addition to studying the important normal function of stem cells in the regeneration of tissues, researchers have further sought to exploit the potential of in situ and/or exogenous stem cells for the treatment of a variety of disorders. While early, embryonic stem cells have generated considerable interest, the stem cells resident in adult tissues may also provide an important source of regenerative capacity.

11/078,899 (7,837,993) The regenerative potential of aged stem cells is enhanced by activation of the Notch signaling pathway and/or inhibition of TGF-ß signaling pathway. Stem cells in aged tissues are capable of proliferation and tissue regeneration, but in their native setting are not provided with the appropriate signals to do so. By administering tissue regenerating agents, organ stem/progenitor cells are provided with the appropriate signals to regenerate the corresponding differentiated tissues.

Field of Use
Licensed Field of Use means therapeutic uses and associated internal research and drug screening activities.

IPSCIO Record ID: 7441

License Grant
The University grants the Licensee an exclusive license, under the Licensed Patents to make, have made, use, sell, have sold, import or export Licensed Products and to practice any licensed method, within the field in the licensed territory.
License Property
The Invention is patent 61/510,812 entitled “Endometrial Derived Stem Cells to Treat Diabetes.

IPSCIO Record ID: 7247

License Grant
University agrees to perform for Sponsor certain research described in the Scope of Work set forth.
License Property
Brown Adipose Identification
Human adipose tissue depots will be procured under approved University IRB protocols. These tissues will be identified to contain brown adipose populations by morphological, immunohistochemical and gene expression profiles that are specific to brown adipose. In addition, whenever possible, identification of brown adipose depots will include PET imaging.

Cell-Line Expansion and Characterization
Cell-lines will be developed and characterized from these brown adipose depots. Characterization of these cell-lines will include growth kinetics, gene expression profile, micro-RNA profile, cell surface marker profile, metabolic activity and differentiation potential (i.e., osteogenesis, chondrogenesis, white and brown adipogenesis). Differentiation will be confirmed by immunocytochemistry, protein expression, gene expression profile and functional assays (i.e., metabolic activity)
Once a brown fat line has been identified, different cell-lines will be generated containing several different constructs with brown fat specific genes (i.e., PRDM16, UCP1,) with downstream reporter genes. These cell-lines will be used for small molecule screening.
Cells will also be cultured on biodegradable scaffolds and induced to differentiate within the scaffold. Metabolic activity of the cellular/scaffold matrix will be determined.

Pre-Clinical Animal Models
After a clinical cell-line with metabolic activity has been identified and characterized, pre-clinical small animal models will be initiated. These animal models will be used to determine the feasibility of using a cell-based approach to treat human metabolic disorders. In addition, if a small molecule has been identified, safety and feasibility testing will be performed.

IPSCIO Record ID: 90081

License Grant
The Spanish Licensor hereby grants to Licensee, and the Swiss Licensee hereby accepts, a license to (i) the Licensor Background IP on or in relation to the Product in the Field and (ii) the Licensor Foreground IP and the Licensor’s interest in Joint Foreground IP on, or in relation to, the Product in the Field generated during the Term of the Agreement, allowing Licensee

*                 on an exclusive basis, to use and Commercialise the Product in the Field in the Territory during the Term under the Licensor Trade Marks;

*                  on an exclusive basis, to register the Product in the Field in any country of the Territory that is outside of the EEA, during the Term;

*                  from the date of the transfer of the Regulatory Approval to the Licensee in the EEA, on an exclusive basis, to register the Product in the Field in any country of the Territory that is within the EEA, during the Term;

*                 on an exclusive basis, to carry out Development in relation to the Product in the Field in the Territory during the Term;

*                  on a non-exclusive basis, to carry out Development (except that for the purposes of this Clause, Development shall not include clinical development) in relation to the Product in the Field outside the Territory for Commercialisation of the Product in the Field in the Territory during the Term;

*                  on an exclusive basis, to manufacture the Product in the Territory for Commercialisation of the Product in the Field in the Territory during the Term;

*                  on an non-exclusive basis, to manufacture the Product outside of the Territory, for Commercialisation of the Product in the Field in the Territory during the Term; and

*                  on a non-exclusive basis, to use the corporate name of Licensor for the purposes and in accordance with the terms set out.

License Property
Product(s) means the Cx601 product of Licensor, defined as a suspension of allogeneic expanded adipose-derived stem cells for local administration resulting from the Product Manufacturing, or any other product whose manufacture, use or sale would, in the absence of a license from Licensor, constitute direct, indirect, contributory or any other type of infringement of one or more claims of the Licensor Intellectual Property Rights;

Licensor Background IP means Intellectual Property Rights held or controlled by Licensor including the Licensor Know-how, Licensor Patents and Licensor Trade Marks (i) existing at the Effective Date or (ii) developed by employees, agents or independent contractors of Licensor during the Term but independently of this Agreement;

Licensor Foreground IP shall refer to such Foreground IP made solely by employees, agents or independent contractors of Licensor during the course of, in furtherance of, and as a direct result of such employees, agents or independent contractors performing an activity pursuant to this Agreement.

Joint Foreground IP shall refer to such Foreground IP made jointly by employees, agents or independent contractors of Licensor and Licensee during the course of, in furtherance of, and as a direct result of such employees, agents or independent contractors performing an activity pursuant to this Agreement.

Licensor Know-how includes

*  Clinical Know-how relating to the Product
This includes the preclinical package, the clinical package and the CMC dossier.

*  Medical Know-how relating to the Product
This includes medical knowledge such as surgical technique and disease management.

*  Market access Know-how relating to the Product
This includes dossiers in respect of pricing and reimbursement, epidemiology and burden of the disease.

*  Manufacturing Know-how relating to the Product
This includes manufacturing know-how and experience, including donor identification.

*  Logistics and transportation Know-how relating to the Product
This includes logistics and transportation know-how and experience, including shipping containers, temperature monitoring, and product shelf-life.

Patents and patent applications belonging to the patent family “Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue.'

Patents and patent applications belonging to the patent family “Use of adipose tissue-derived stromal stem cells in treating fistula.'

Field of Use
The Field means the treatment of human diseases in the Primary Indication.

IPSCIO Record ID: 203392

License Grant
The University grants to Licensee a world-wide license under the Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.

The University also grants to Licensee the right to issue sublicenses to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method, as long as Licensee has current exclusive rights thereto under this Agreement, except that the sublicensee may not be granted the right to further sublicense the technology.

License Property
The technology and patents are for certain inventions, generally characterized as Connective Tissue Stem Cells.  The Cell Replacement Therapy means the use of adipose-derived stem cells for the therapeutic replacement of cells and tissues damaged by disease or injury.
Field of Use
The Field of Use means Cell Replacement Therapy in humans; Gene Therapy in humans; Cosmetic Surgery and Reconstructive Surgery in humans; Research and Collaboration Services; and the development and commercialization of Consumables.

IPSCIO Record ID: 328348

License Grant
For the License,  Licensor, nonprofit technology transfer organization serving the University, grants a nonexclusive license, limited to the Licensed Field and the Licensed Territory, under the Licensed Patents to make, use and sell Products .

For the Option to Expand the Licensed Field, Licensor grants an option to expand the field of use to include Products for non-primate, Including non-human, fields of use in the Licensed Field under this Agreement.

For a Period of Exclusivity, Licensor grants a one-year period of exclusivity for which Licensee shall pay a fee.

License Property
The patent application relates to primate embryonic stem cells.

Licensed Patents shall refer to and mean United States Patent Application Serial No. 08/376,327 and any foreign equivalents.

Field of Use
Licensed Field shall be limited to the field of primate, including human, diagnostic and therapeutic treatment.

Licensor is a biopharmaceutical company exclusively focused on discovering and developing therapeutic and diagnostic products based upon common biological mechanisms underlying cancer and other age-related diseases.

IPSCIO Record ID: 4220

License Grant
The Licensor, a University, has granted the Licensee an exclusive, worldwide License, under its patents relating to flow sorting of stem cell populations based on a fluorescent ALDH substrate.
License Property
The Licensee bears all costs to maintain the patents.
Field of Use
The Aldagen technology utilizes an intracellular enzyme marker to fractionate essential regenerative cells from a patient’s bone marrow. This proprietary bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation. The selected biologically instructive cells (ALDHbr) have the potential to promote the repair and regeneration of multiple types of cells and tissues, including the growth of new blood vessels, or angiogenesis, which is critical to the generation of healthy tissue.

IPSCIO Record ID: 6982

License Grant
University hereby grants to Licensee a royalty-bearing exclusive license to make, have made, use and sell any Licensed Product and to practice any Licensed Method in the Field of Use under Licensor’s Patent Rights throughout the Territory.
License Property
Proprietary biocompatible hydrogels mimic the extracellular matrix in which cells reside.

Certain inventions, generally characterized as and assigned University identification number U-3405, “In situ Crosslinkable Synthetic Extracellular Matrices”, and U-3656, “Novel Chemical Modifications of Hyaluronan”,

U No.

Matter

Application No.  Date of Filing

Title

Inventor(s)

U-3405

21101.0036U1  Provisional

60/390,504  6/21/2002

Disulfide Crosslinked Hyaluronan Hydrogels

Glenn Preswich, Xiao Shu, Yi Luo, Kelly Kirker

U-3405

21101.0036P1  PCT

PCT/US03/15519  5/15/03

Crosslinked Compounds and Methods of Making and Using Thereof

Glenn Preswich, Xiao Shu, Yi Luo, Kelly Kirker

U-3405

21101.0036U2  Nationalized, United States

10/519,173  12/20/04

Crosslinked Compounds and Methods of Making and Using Thereof

Glenn Preswich, Xiao Shu, Yi Luo, Kelly Kirker

U-3405

21101.0036CA1  Nationalized, Canada

2,489,712  5/15/03

Crosslinked Compounds and Methods of Making and Using Thereof

Glenn Preswich, Xiao Shu, Yi Luo, Kelly Kirker

U-3405

21101.0036EP1  Nationalized, Europe

03799796.2  5/15/03

Crosslinked Compounds and Methods of Making and Using Thereof

Glenn Preswich, Xiao Shu, Yi Luo, Kelly Kirker

U-3656

21101.0051P1  Provisional

60/526,797  12/4/2003

Modified Macromolecules and Methods of Making and Using Thereof

Glenn Prestwich, Xiao Shu

U-3656

21101.0051U1  PCT

PCT/US04/040726  12/6/2004

Modified Macromolecules and Methods of Making and Using Thereof

Glenn Prestwich, Xiao Shu

Field of Use
Licensee intend to initially use the technology in the development of therapeutic products for use in the treatment of osteoarthritis.

HyStem®-Rx is a biocompatible hydrogel that mimics the extracellular matrix in which cells reside. As an injectable product, HyStem®-Rx may address an immediate need in cosmetic and reconstructive surgery and other procedures by improving the process of transplanting adipose (fat) cells or other adult stem cells. Adult stem cell types such as adipose stem cells obtained from a patient through liposuction can be transplanted back into the same patient in another location in the body, without the risk of rejection associated with the transplant of donor tissues.

The Licensee is developing cellular therapeutics for orthopedic repair diseases and injuries. The lead project is the development of human embryonic progenitor cell (hEPC) lines for cartilage repair. A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient.

IPSCIO Record ID: 286096

License Grant
Whereas, the University, has waived its interest to certain parts of the Technology, inter alia, the multipotent postnatal derived progenitor cells, and that waived part of the Technology, which is now Licensee Company Technology is assigned to and owned by the Licensee; and
Whereas, the remaining part of the Technology, known as the University Technology, is owned by the University and ownership of the Licensee Technology and the University Technology is governed by a separate agreement between the University and the Licensee,
The University is granting to the Licensee an exclusive license to the University Technology.

The University grants an irrevocable, exclusive right and license in any and all Fields of Use, including the right to sub license to Affiliates or unrelated third parties, to the Licensed Patents and the University Technology to make, have made, use, sell, offer to sell, import and export, lease or otherwise dispose of Licensed Product in the Territory.

License Property
The University developed Technology relating to multipotent postnatal derived progenitor cells, their precursors, progeny and components, products made therefrom, processes used in their production and processing, and methods for their use.

The technology shall mean Licensees Technology and University Technology, including but not limited to, multipotent postnatal derived progenitor cells, precursors, progeny or components thereof, products and information obtained from the foregoing, processes and products utilized in production or processing of any of the foregoing, methods of utilizing any of the foregoing, and any Trade Secret Information or know-how relating to the foregoing. The term Technology shall also include any invention involving multipotent postnatal derived progenitor cells (a) that is the result of research conducted.

Licensed Patent shall mean a Patent that claims as an invention one or more aspects of the Technology.

Licensed Product shall mean any Technology which is within the scope of one or more claims of a Licensed Patent and, but for the license granted in this Agreement, would infringe, constitute contributory infringement, or constitute inducement to infringe of one or more such claims when made by, made for, used, sold, offered for sale, imported, exported, leased, or otherwise disposed of by the Licensee.

Field of Use
The Field of Use shall mean any and all fields of use, including but not limited to diagnostic, therapeutic and research applications.

Lysosomal storage disorders are a group of more than 40 recessive genetic diseases resulting in deficiencies in lysosomal acid hydrolases. Although individually rare, lysosomal storage disorders have a prevalence of 1 per 7700 live births. Such diseases include Gaucher's disease, Fabry disease, Niemann-Pick disease, mucopolysaccharidoses Type I through VII, Tay-Sachs disease, among many others. Loss of lysosomal enzyme activity results in the progressive accumulation of undegraded substrate within the lysosomes, resulting in engorgement of the organelle, subsequent cellular, tissue, and organ dysfunction, and often death. Lysosomal storage diseases affect multiple organ systems, many of them before birth, resulting in irreversible defects. Clinical treatments for metabolic storage disorders are limited to bone marrow transplantation and enzyme replacement therapy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.